I am a board-certified medical oncologist whose clinical practice is dedicated exclusively to the care of patients with all stages of breast cancer. I am part of a large, multidisciplinary team of devoted specialists who share my goal of providing exceptional care to patients fighting breast cancer. Through my research activities, I work to develop new therapeutic options for the treatment of breast cancer and to ultimately eradicate this disease.
My research has centered on the use of novel, targeted therapies for the treatment of triple negative breast cancer (TNBC). Currently, I am the lead investigator for a multicenter trial studying the use of androgen receptor inhibition for patients with advanced TNBC. I have investigated numerous other targets for treatment of this subtype of breast cancer, including src and PARP, and have collaborated to develop biologic predictors of response to conventional therapies such as platinum. I have also had a special interest in optimizing drug delivery schedules to minimize side effects of treatment while maximizing its benefits.